CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has signed an agreement with a leading reference laboratory in Canada to install CellaVision® DM96 analyzers at two of their medical service laboratories in Canada. The order comprises CellaVision DM96 analyzers for automation of the manual differential and CellaVision's software for remote access to patient's cell images."This order, from one of the leading reference laboratories in Canada, is a strategically important step as we now expand our direct sales in North America", says Yvonne Mårtensson, CEO of CellaVision"The trust placed in us through this order is confirmation that we deliver first class products and support, and meet the Canadian customers' high demands of automation and cost reductions." The reference laboratory chooses CellaVision products to reduce the total labor spent performing manual differentials and to bridge geographical distances between the two laboratories. The CellaVision® Remote Review Software will improve the turnaround time for consultation on difficult cases, and slides can be reviewed by the expert in real-time from either lab, with results now available in minutes instead of hours. The remote capability will also allow one lab to perform the other's work if necessary, providing staffing flexibility for both sites. North America is one of CellaVision's most important markets. The company has had a subsidiary in Canada since 2007. In the US, CellaVision is represented by its distributor Sysmex America and a subsidiary in Florida. In 2007, North America counted for approximately 40 percent of CellaVision's total turnover. Fore more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 46-286 44 00. E-mail: yvonne.martensson@cellavision.com About CellaVision CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy. The company headquarters are in Lund, Sweden. The company also has subsidiaries in Jupiter, FL, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com. CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.